期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 14, 期 12, 页码 717-734出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2017.101
关键词
-
类别
资金
- Institut National de la sante et de la Recherche Medicale (INSERM)
- University Paris-Descartes
- University Pierre and Marie Curie
- Site de Recherche Integree sur le Cancer (SIRIC) Cancer Research for Personalized Medicine (CARPEM) programme
- LabEx Immuno-Oncology
- Institut National Du Cancer (INCa)
- Canceropole Ile-de-France
- O. Lecomte
- Association pour la recherche sur le cancer (ARC)
- INCa
- Ligue contre le Cancer (equipe labellisee)
- Agence National de la Recherche (ANR) - Projets blancs
- ANR under the frame of E-Rare-2
- ERA-Net for Research on Rare Diseases
- ARC
- Cancerople Ile-de-France
- INSERM (HTE)
- Institut Universitaire de France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- SIRIC Stratified Oncology Cell DNA Repair and Tumour Immune Elimination (SOCRATE)
- CARPEM
- Paris Alliance of Cancer Research Institutes (PACRI)
- Swiss Institute for Experimental Cancer Research (ISREC)
- Swiss Bridge Foundation
- IMMUNTRAIN-H
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters. Several complementary technologies can be used to explore the immune contexture of tumours, and to derive biomarkers that could enable the adaptation of individual treatment approaches for each patient, as well as monitoring a response to anticancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据